{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:20:32Z","timestamp":1790835632948,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The National Natural Science Foundation of China (Regional Science Foundation Project","award":["81860292"],"award-info":[{"award-number":["81860292"]}]},{"name":"The National Natural Science Foundation of China (Regional Science Foundation Project","award":["82060300"],"award-info":[{"award-number":["82060300"]}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2020JJA140100"],"award-info":[{"award-number":["2020JJA140100"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi medical and health technology development and promotion project","award":["S2018084"],"award-info":[{"award-number":["S2018084"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study explored the role of IL-35 in CD4+ T lymphocyte and human skin fibroblast (HSF) activity and cytokine levels in systemic sclerosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Blood and skin biopsies were collected from 41 patients and 39 healthy controls to assess CD4+ T lymphocytes and IL-35-related factors. CD4+ T lymphocytes were co-cultured with HSFs, recombinant human IL-35 and IL-35 mAb to evaluate the cell viability, activation of CD4+ T lymphocytes and HSF cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The proportion of blood Th1\/Th2 was lower and Th17\/Treg was higher in patients than in controls (P\u2009&amp;lt;\u20090.05). IL-35 and IL-17A levels were higher and IFN-\u03b3, IL-10 and TGF-\u03b2 levels were lower in patients than in controls. IL-17A, forkhead box P3, TGF-\u03b21 and collagen type I (COL-1) mRNA and phospho (p)-signal transducer and activator of transcription (STAT) 1 and p-STAT4 were higher in skin tissues from patients than in those from controls (P\u2009&amp;lt;\u20090.05). IL-6 levels were higher, whereas IL-10 levels were lower in cell culture supernatants. \u03b1-Smooth muscle actin (\u03b1-SMA) and COL-1 proteins and Ki67 positivity were higher in CD4+ T + HSF cells from patients than in those from controls. Recombinant human IL-35 treatment inhibited proliferation (P\u2009&amp;lt;\u20090.001), but increased IL-10 and decreased IL-17A, \u03b1-SMA and COL-1 secretion into the conditioned medium of CD4+ T lymphocytes + HSFs from patients compared with those from controls. IL-35 mAb blocked the effects of IL-35 in CD4+ T + HSF cells (P\u2009&amp;lt;\u20090.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IL-35 plays an inhibitory role in CD4+ T lymphocyte proliferation but induces Treg cell differentiation by STAT1 signalling activation, HSF proliferation and collagen expression in systemic sclerosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab359","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T11:22:23Z","timestamp":1618658543000},"page":"794-805","source":"Crossref","is-referenced-by-count":20,"title":["Altered CD4+ T cell and cytokine levels in peripheral blood and skin samples from systemic sclerosis patients and IL-35 in CD4+ T cell growth"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-2828","authenticated-orcid":false,"given":"Chenxi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"2022020819080142500_keab359-B1","first-page":"94","article-title":"Incidence, prevalence and disease characteristics of systemic sclerosis in Split-Dalmatia County","volume":"57","author":"Kaliterna","year":"2010","journal-title":"Reumatizam"},{"key":"2022020819080142500_keab359-B2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.17219\/acem\/64334","article-title":"Systemic sclerosis sine scleroderma","volume":"26","author":"Kucharz","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"2022020819080142500_keab359-B3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis","volume":"24","author":"Barnes","year":"2012","journal-title":"Cur Opin Rheumatol"},{"key":"2022020819080142500_keab359-B4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-140-1-200401060-00010","article-title":"Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis","volume":"140","author":"Jimenez","year":"2004","journal-title":"Ann Intern Med"},{"key":"2022020819080142500_keab359-B5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/exd.14179","article-title":"Frontiers in translational systemic sclerosis research: a focus on the unmet cutaneous' clinical needs","volume":"29","author":"Herrick","year":"2020","journal-title":"Exp Dermatol"},{"key":"2022020819080142500_keab359-B6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17402520500233437","article-title":"New therapeutic strategies for systemic sclerosis \u2013 a critical analysis of the literature","volume":"12","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"2022020819080142500_keab359-B7","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2022020819080142500_keab359-B8","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022020819080142500_keab359-B9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00403-005-0635-z","article-title":"The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?","volume":"297","author":"Yamamoto","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"2022020819080142500_keab359-B10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.autrev.2010.08.003","article-title":"Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis","volume":"10","author":"Baraut","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2022020819080142500_keab359-B11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/BOR.0000000000000735","article-title":"Systemic sclerosis pathogenesis: contribution of recent advances in genetics","volume":"32","author":"Orvain","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2022020819080142500_keab359-B12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/jcm9092687","article-title":"The pathogenesis of systemic sclerosis: an understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies","volume":"9","author":"Asano","year":"2020","journal-title":"J Clin Med"},{"key":"2022020819080142500_keab359-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/030.63.2016.1.1","article-title":"IL-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and signalling pathways","volume":"63","author":"Behzadi","year":"2016","journal-title":"Acta Microbiol Immunol Hungari"},{"key":"2022020819080142500_keab359-B14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"2022020819080142500_keab359-B15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.autrev.2018.01.017","article-title":"Emerging role of IL-35 in inflammatory autoimmune diseases","volume":"17","author":"Su","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2022020819080142500_keab359-B16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat Immunol"},{"key":"2022020819080142500_keab359-B17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat Immunol"},{"key":"2022020819080142500_keab359-B18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RHU.0000000000000947","article-title":"Serum interleukin 35 levels in systemic sclerosis and relationship with clinical features","volume":"26","author":"Yayla","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"2022020819080142500_keab359-B19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00296-018-4071-8","article-title":"Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis","volume":"38","author":"Tang","year":"2018","journal-title":"Rheumatol Int"},{"key":"2022020819080142500_keab359-B20","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.4049\/jimmunol.1402362","article-title":"EBI3 downregulation contributes to type I collagen overexpression in scleroderma skin","volume":"195","author":"Kudo","year":"2015","journal-title":"J Immunol"},{"key":"2022020819080142500_keab359-B21","first-page":"2273","article-title":"Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease","volume":"54","author":"Michal","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2022020819080142500_keab359-B22","first-page":"2737","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR Collaborative Initiative","volume":"65","author":"Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022020819080142500_keab359-B23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00011-011-0419-1","article-title":"Th17 cell cytokine secretion profile in host defense and autoimmunity","volume":"61","author":"Graeber","year":"2012","journal-title":"Inflamm Res"},{"key":"2022020819080142500_keab359-B24","first-page":"14","article-title":"Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis","volume":"34","author":"Lei","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022020819080142500_keab359-B25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nri3605","article-title":"Homeostatic control of regulatory T cell diversity","volume":"14","author":"Liston","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2022020819080142500_keab359-B26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2011.01.013","article-title":"Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis","volume":"139","author":"Fenoglio","year":"2011","journal-title":"Clin Immunol"},{"key":"2022020819080142500_keab359-B27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/03009742.2010.528021","article-title":"Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis","volume":"40","author":"Papp","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"2022020819080142500_keab359-B28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2010.09633.x","article-title":"Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea","volume":"162","author":"Antiga","year":"2010","journal-title":"Br J Dermatol"},{"key":"2022020819080142500_keab359-B29","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022020819080142500_keab359-B30","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"2022020819080142500_keab359-B31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imlet.2018.03.011","article-title":"Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations","volume":"198","author":"Dantas","year":"2018","journal-title":"Immunol Lett"},{"key":"2022020819080142500_keab359-B32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/wound.2019.1032","article-title":"The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis","volume":"9","author":"Steen","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"2022020819080142500_keab359-B33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"2022020819080142500_keab359-B34","doi-asserted-by":"crossref","first-page":"73003","DOI":"10.18632\/oncotarget.12193","article-title":"Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1\/STAT3","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"2022020819080142500_keab359-B35","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur J Immunol"},{"key":"2022020819080142500_keab359-B36","doi-asserted-by":"crossref","first-page":"e33628","DOI":"10.1371\/journal.pone.0033628","article-title":"IL-35 is a novel responsive anti-inflammatory cytokine\u2014a new system of categorizing anti-inflammatory cytokines","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"2022020819080142500_keab359-B37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.micro.091208.073413","article-title":"Biological functions and biogenesis of secreted bacterial outer membrane vesicles","volume":"64","author":"Kulp","year":"2010","journal-title":"Annu Rev Microbiol"},{"key":"2022020819080142500_keab359-B38","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1053\/j.gastro.2011.07.040","article-title":"Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis","volume":"141","author":"Wirtz","year":"2011","journal-title":"Gastroenterology"},{"key":"2022020819080142500_keab359-B39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"key":"2022020819080142500_keab359-B40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-017-00838-4","article-title":"IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease","volume":"8","author":"Dambuza","year":"2017","journal-title":"Nat Commun"},{"key":"2022020819080142500_keab359-B41","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/eji.200838145","article-title":"Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and ROR\u03b3t","volume":"38","author":"Yang","year":"2008","journal-title":"Eur J Immunol"},{"key":"2022020819080142500_keab359-B42","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/kex347","article-title":"Role of STAT3 in skin fibrosis and transforming growth factor beta signalling","volume":"57","author":"Pedroza","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022020819080142500_keab359-B43","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","article-title":"Unraveling SSc pathophysiology; the myofibroblast","volume":"9","author":"van Caam","year":"2018","journal-title":"Front Immunol"},{"key":"2022020819080142500_keab359-B44","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehy188","article-title":"Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis","volume":"40","author":"Rodriguez","year":"2019","journal-title":"Eur Heart J"},{"key":"2022020819080142500_keab359-B45","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/15548627.2017.1328348","article-title":"Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4","volume":"13","author":"Tsubouchi","year":"2017","journal-title":"Autophagy"},{"key":"2022020819080142500_keab359-B46","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jid.2018.01.016","article-title":"Spatial and single-cell transcriptional profiling identifies functionally distinct human dermal fibroblast subpopulations","volume":"138","author":"Philippeos","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2022020819080142500_keab359-B47","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2022020819080142500_keab359-B48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.30171","article-title":"Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022020819080142500_keab359-B49","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10753-016-0453-9","article-title":"Interleukin-35: a potential therapeutic agent for autoimmune diseases","volume":"40","author":"Guan","year":"2017","journal-title":"Inflammation"},{"key":"2022020819080142500_keab359-B50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/1744666X.2019.1564041","article-title":"The immunomodulatory role of interleukin-35 in fibrotic diseases","volume":"15","author":"Luo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2022020819080142500_keab359-B51","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s10067-015-3006-y","article-title":"Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement","volume":"34","author":"Dantas","year":"2015","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab359\/38712096\/keab359.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/2\/794\/42368557\/keab359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/2\/794\/42368557\/keab359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T19:09:24Z","timestamp":1644347364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/2\/794\/6241494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4,20]]},"published-print":{"date-parts":[[2022,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab359","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,4,20]]}}}